Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.
Psoriatic patients have a higher prevalence of diabetes mellitus type 2 (DM). Since dipeptidyl peptidase IV (DPP-IV) dysregulation is present in DM and psoriasis, DPP-IV inhibitors have been proposed as therapeutic agents for both conditions. We report a psoriasiform eruption induced by sitagliptin, a DPP-IV inhibitor. The role of DPP-IV in the pathogenesis of DM is well established; however data on psoriatic patients is contradictory. More studies are required to elucidate the effect of DPP-IV inhibitors and their relationship with DM and psoriasis.
Department of Dermatology, University Hospital of Asturias, Oviedo, Spain. albert.mas.vidal@gmail.com
Albert
A
Mas-Vidal
Jorge
J
Santos-Juanes
Altea
A
Esteve-Martinez
Luis
L
Caminal-Montero
Pablo
P
Coto-Segura
D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D005121:Extremities; D005260:Female; D006801:Humans; D008875:Middle Aged; D011565:Psoriasis / Q000139:chemically induced* / Q000453:epidemiology; D011719:Pyrazines / Q000009:adverse effects*; D000068900:Sitagliptin Phosphate; D060726:Torso; D014230:Triazoles / Q000009:adverse effects*
D054873:Dipeptidyl-Peptidase IV Inhibitors; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate